Section Arrow
NBIX.NASDAQ
- Neurocrine Biosciences
Quotes are at least 15-min delayed:2025/12/01 11:44 EST
Regular Hours
Last
 150.69
-1.47 (-0.97%)
Day High 
153.29 
Prev. Close
152.16 
1-M High
157.67 
Volume 
142.70K 
Bid
150.58
Ask
150.82
Day Low
149.58 
Open
152.38 
1-M Low
133.61 
Market Cap 
15.17B 
Currency 美元 
P/E 36.75 
%Yield -- 
10-SMA 143.44 
20-SMA 145.6 
50-SMA 142.75 
52-W High 157.67 
52-W Low 84.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.19/6.87
Enterprise Value
15.63B
Balance Sheet
Book Value Per Share
30.12
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
2.36B
Operating Revenue Per Share
17.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands0.7834-0.0296-3.64%-- 
CGCCanopy Growth Corp1.15-0.02-1.71%-- 
HIMSHims & Hers Health38.6-1.16-2.92%74.91PE
HLNHaleon plc9.835+0.055+0.56%22.11PE
IXHLIncannex Healthcare0.3693+0.0091+2.53%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.